RBC Capital analyst Luva Issi initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Outperform rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage